Equity Profile

BDX

Becton, Dickinson and Company

Health CareHealth Care Equipment$41.7B

Aug6Thu

Pre-Earnings Brief

UpcomingQ3-2026Pre-Market9:00 AM EDT

Company Snapshot

Becton, Dickinson and Company (BDX) is a global medical technology company that develops and manufactures a wide range of medical devices, instrument systems, and reagents. Operating in the health care sector, BDX plays a crucial role in improving patient care and enhancing the efficiency of health care delivery.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and drive sales, which is vital for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

BDX Q3-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+4.98%

Avg Stock Reaction

-1.31%

Last Quarter Recap

In Q2 2026, BDX reported an EPS of $2.90, exceeding expectations by 4.73%. The stock reacted positively, gaining 5.87% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of BDX's upcoming earnings report, given the company's consistent EPS beats in recent quarters.

Bull Case

If BDX continues its trend of beating EPS estimates, it could signal strong operational performance and market demand, leading to a positive stock reaction.

Bear Case

Conversely, if BDX fails to meet expectations or provides weak guidance, it could raise concerns about future growth and negatively impact the stock.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q3-2026, and how does it compare to previous quarters?

Given BDX's strong track record of beating EPS estimates, the market will closely watch this figure to gauge ongoing profitability.

What insights will management provide on revenue growth and market demand?

Understanding revenue growth will be critical for assessing the company's future trajectory and overall health in the competitive medical technology sector.

Edge

What the Street Is Missing

Why consensus could be wrong

While the Street expects BDX to maintain its EPS beat trend, the lack of revenue guidance could indicate underlying challenges that are not being fully accounted for.

Supporting Evidence

Options are pricing a 12.83% move, suggesting heightened uncertainty not reflected in the consensus outlook.

The recent stock reaction patterns indicate that even small misses can lead to significant declines, which may not be fully appreciated by the market.

Key Risk

If revenue growth does not meet expectations, it could undermine the bullish sentiment surrounding BDX.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is under scrutiny as BDX has consistently beaten EPS estimates, but any sign of weakness could shift investor sentiment.

Bull Confirmed If

An EPS of $3.00 or higher would confirm the bull case and suggest strong operational performance.

Bear Confirmed If

An EPS below $2.70 would raise concerns and confirm the bear case regarding future growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±12.83%

Historical Avg

±5.4%

Pricing rich

The options market is pricing in a significant potential move, indicating uncertainty about the upcoming earnings report.

Options are pricing ±12.0% while BDX has averaged ±5.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

32.1%

Calls (185K)P/C Ratio: 0.46Puts (149K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BDX beats expectations, history suggests a potential stock increase of around 5.41%, confirming strong operational momentum.

In-Line / Cautious

A cautious in-line report could lead to muted reactions as investors await further clarity on future growth prospects.

Miss

If BDX misses expectations, history suggests a potential decline of around 1.31%, raising concerns about the company's growth trajectory.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·1 sell

Members

House only

Est. Notional

$15,001.00–$50,000.00

disclosed dollar ranges

Most Active Members

R-OKKevin HernRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product demand and market trends in the medical technology sector.
2Management's commentary on cost management and operational efficiency initiatives.
3Insights into new product launches or innovations that could drive future growth.
4Any changes in guidance or outlook for the remainder of the fiscal year.
5Details on competitive dynamics and how BDX plans to maintain its market position.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and drive sales, which is vital for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

BDX Q3-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+4.98%

Avg Stock Reaction

-1.31%

Last Quarter Recap

In Q2 2026, BDX reported an EPS of $2.90, exceeding expectations by 4.73%. The stock reacted positively, gaining 5.87% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of BDX's upcoming earnings report, given the company's consistent EPS beats in recent quarters.

Bull Case

If BDX continues its trend of beating EPS estimates, it could signal strong operational performance and market demand, leading to a positive stock reaction.

Bear Case

Conversely, if BDX fails to meet expectations or provides weak guidance, it could raise concerns about future growth and negatively impact the stock.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q3-2026, and how does it compare to previous quarters?

Given BDX's strong track record of beating EPS estimates, the market will closely watch this figure to gauge ongoing profitability.

What insights will management provide on revenue growth and market demand?

Understanding revenue growth will be critical for assessing the company's future trajectory and overall health in the competitive medical technology sector.

Edge

What the Street Is Missing

Why consensus could be wrong

While the Street expects BDX to maintain its EPS beat trend, the lack of revenue guidance could indicate underlying challenges that are not being fully accounted for.

Supporting Evidence

Options are pricing a 12.83% move, suggesting heightened uncertainty not reflected in the consensus outlook.

The recent stock reaction patterns indicate that even small misses can lead to significant declines, which may not be fully appreciated by the market.

Key Risk

If revenue growth does not meet expectations, it could undermine the bullish sentiment surrounding BDX.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is under scrutiny as BDX has consistently beaten EPS estimates, but any sign of weakness could shift investor sentiment.

Bull Confirmed If

An EPS of $3.00 or higher would confirm the bull case and suggest strong operational performance.

Bear Confirmed If

An EPS below $2.70 would raise concerns and confirm the bear case regarding future growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±12.83%

Historical Avg

±5.4%

Pricing rich

The options market is pricing in a significant potential move, indicating uncertainty about the upcoming earnings report.

Options are pricing ±12.0% while BDX has averaged ±5.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

32.1%

Calls (185K)P/C Ratio: 0.46Puts (149K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BDX beats expectations, history suggests a potential stock increase of around 5.41%, confirming strong operational momentum.

In-Line / Cautious

A cautious in-line report could lead to muted reactions as investors await further clarity on future growth prospects.

Miss

If BDX misses expectations, history suggests a potential decline of around 1.31%, raising concerns about the company's growth trajectory.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·1 sell

Members

House only

Est. Notional

$15,001.00–$50,000.00

disclosed dollar ranges

Most Active Members

R-OKKevin HernRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product demand and market trends in the medical technology sector.
2Management's commentary on cost management and operational efficiency initiatives.
3Insights into new product launches or innovations that could drive future growth.
4Any changes in guidance or outlook for the remainder of the fiscal year.
5Details on competitive dynamics and how BDX plans to maintain its market position.